Then, we further performed IHC staining and found consistent results (Figure 7F; Figure S9B, Supporting Information), which supported that the concurrent administration of a CXCR2 inhibitor targeting the CXCL5 cognate receptor, AB680, and PD‐1 inhibitor has the potential to impede the recruitment of immunosuppressive MDSCs caused by AB680 and significantly boost the antitumor immune responses to restrain tumor growth. Here, CXCR2 is linked to neoplasm.